Cited by 1,506Atrial Fibrillation Management and OutcomesCardiac Valve Diseases and TreatmentsVenous Thromboembolism Diagnosis and Management

The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.

Dabigatran versus Warfarin in Patients with Mechanical Heart Valves

Eikelboom, John W., Connolly, Stuart J., Brueckmann, Martina, Granger, Christopher B., Kappetein, Arie P., Mack, Michael J., Blatchford, Jon, Devenny, Kevin, Friedman, Jeffrey, Guiver, Kelly, Harper, Ruth, Khder, Yasser, Lobmeyer, Maximilian T., Maas, Hugo, Voigt, Jens-Uwe, Simoons, Maarten L., Van de Werf, Frans·2013·New England Journal of Medicine

DOI 10.1056/nejmoa1300615

Open this paper in CoChat — free account

Abstract

BACKGROUND: Dabigatran is an oral direct thrombin inhibitor that has been shown to be an effective alternative to warfarin in patients with atrial fibrillation. We evaluated the use of dabigatran in patients with mechanical heart valves. METHODS: In this phase 2 dose-validation study, we studied two populations of patients: those who had undergone aortic- or mitral-valve replacement within the past 7 days and those who had undergone such replacement at least 3 months earlier. Patients were randomly assigned in a 2:1 ratio to receive either dabigatran or warfarin. The selection of the initial dabigatran dose (150, 220, or 300 mg twice daily) was based on kidney function. Doses were adjusted to obtain a trough plasma level of at least 50 ng per milliliter. The warfarin dose was adjusted to obtain an international normalized ratio of 2 to 3 or 2.5 to 3.5 on the basis of thromboembolic risk. The primary end point was the trough plasma level of dabigatran. RESULTS: The trial was terminated prematurely after the enrollment of 252 patients because of an excess of thromboembolic and bleeding events among patients in the dabigatran group. In the as-treated analysis, dose adjustment or discontinuation of dabigatran was required in 52 of 162 patients (32%). Ischemic or unspecified stroke occurred in 9 patients (5%) in the dabigatran group and in no patients in the warfarin group; major bleeding occurred in 7 patients (4%) and 2 patients (2%), respectively. All patients with major bleeding had pericardial bleeding. CONCLUSIONS: The use of dabigatran in patients with mechanical heart valves was associated with increased rates of thromboembolic and bleeding complications, as compared with warfarin, thus showing no benefit and an excess risk. (Funded by Boehringer Ingelheim; ClinicalTrials.gov numbers, NCT01452347 and NCT01505881.).

Integrity signals

Registry

Crossref · 10.1056/nejmoa1300615

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients
Schulman, S., & Kearon, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,025
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients
Schulman, S., Angerås, U., Bergqvist, D., ERIKSSON, B., Lassen, M. R., & FISHER, W. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,761
Guidelines on the management of valvular heart disease (version 2012)
Authors/Task Force Members, Vahanian, A., Alfieri, O., Andreotti, F., Antunes, M. J., Barón-Esquivias, G., Baumgartner, H., Borger, M. A., Carrel, T. P., De Bonis, M., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs109 · Cited by 3,559
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,070
Oral Anticoagulant Therapy
Ageno, W., Gallus, A. S., Wittkowsky, A. K., Crowther, M. A., Hylek, E. M., & Palareti, G. (2012) · CHEST Journal · doi:10.1378/chest.11-2292 · Cited by 1,583
Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium
Leon, M. B., Piazza, N., Nikolsky, E., Blackstone, E. H., Cutlip, D. E., Kappetein, A. P., Krucoff, M. W., Mack, M. J., Mehran, R., Miller, D. C., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehq406 · Cited by 1,217
Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited
Watson, T., Shantsila, E., & Lip, G. Y. H. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60040-4 · Cited by 1,124

Flagged first, then by citations

Show all 27 references

1 of the 27 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Dewanjee MK, 1999, J Heart Valve Dis, 8, 324

Sorted by citations

Items 101–200 of 1,000

Apixaban in Patients With Atrial Fibrillation After Transfemoral Aortic Valve Replacement
Seeger, J., Gonska, B., Rodewald, C., Rottbauer, W., & Wöhrle, J. (2017) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2016.10.023 · Cited by 154
Effects of Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta‐Analysis
Pan, K., Singer, D. E., Ovbiagele, B., Wu, Y., Ahmed, M., & Lee, M. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005835 · Cited by 155
Reversal of anticoagulants: an overview of current developments
Thiele, T., Selleng, K., & Greinacher, A. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-11-0982 · Cited by 150
Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis
Zuily, S., Cohen, H., Isenberg, D. A., Woller, S. C., Crowther, M. A., Dufrost, V., Wahl, D. G., Doré, C. J., Cuker, A. C., Carrier, M., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14935 · Cited by 160
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1
Diener, H., Aisenberg, J., Ansell, J., Atar, D., BREITHARDT, G. E., Eikelboom, J. W., Ezekowitz, M. D., Granger, C. B., Halperin, J. L., Hohnloser, S. H., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv643 · Cited by 147
Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation
Zirlik, A., & Bode, C. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1446-0 · Cited by 158
Misconceptions, diagnostic challenges and treatment opportunities in bioprosthetic valve thrombosis: lessons from a case series
Pislaru, S. V., Hussain, I., Pellikka, P. A., Maleszewski, J. J., Hanna, R. D., Schaff, H. V., & Connolly, H. M. (2014) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezu201 · Cited by 143
Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis
Halvorsen, S., Storey, R. F., Rocca, B., Sibbing, D., ten Berg, J. M., Grove, E. L., Weiss, T. W., Collet, J., Andreotti, F., Gulba, D. C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw454 · Cited by 148
Laboratory Monitoring of Non–Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation
Eikelboom, J. W., Quinlan, D. J., Hirsh, J., Connolly, S. J., & Weitz, J. I. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.0364 · Cited by 145
Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial
Caterina, R. D., Renda, G., Carnicelli, A., Nordio, F., Trevisan, M., Mercuri, M. F., Ruff, C. T., Antman, E. M., Braunwald, E., & Giugliano, R. P. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.12.031 · Cited by 149
16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends
Cohen, H., Cuadrado, M. J., Erkan, D., Duarte‐García, A., Isenberg, D. A., Knight, J. S., Ortel, T. L., Rahman, A., Salmon, J. E., Tektonidou, M. G., et al. (2020) · Lupus · doi:10.1177/0961203320950461 · Cited by 170
Direct Oral Anticoagulants: A Quick Guide
Julia, S., & Uprichard, J. (2017) · European Cardiology Review · doi:10.15420/ecr.2017:11:2 · Cited by 150
Factor XI and contact activation as targets for antithrombotic therapy
Gailani, D., Bane, C. E., & Gruber, A. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13005 · Cited by 138
Pregnancy Complicated by Valvular Heart Disease: An Update
Nanna, M. G., & Stergiopoulos, K. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000712 · Cited by 138
Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE)
Lip, G. Y. H., Collet, J., Caterina, R. D., Fauchier, L., Lane, D. A., Larsen, T. B., Marín, F. R., Morais, J., Narasimhan, C., Olshansky, B., et al. (2017) · EP Europace · doi:10.1093/europace/eux240 · Cited by 141
Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs
Verheugt, F. W. A., & Granger, C. B. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60245-8 · Cited by 137
Anticoagulation and Antiplatelet Strategies After On-X Mechanical Aortic Valve Replacement
Puskas, J. D., Gerdisch, M., Nichols, D., Fermin, L., Rhenman, B. E., Kapoor, D., Copeland, J. G., Quinn, R. D., Hughes, G. C., Azar, H., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.535 · Cited by 133
“II 54 (53) 55 (56) 73 (38) 73 (39) III 19 (19) 19 (19) 51 (27) 50 (27) IV 1 (1) 1 (1) 16 (8) 7 (4) Unknown 7 (7) 3 (3) 14 (7) 16 (9)”
JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias
Ono, K., Iwasaki, Y., Akao, M., Ikeda, T., Ishii, K., Inden, Y., Kusano, K., Kobayashi, Y., Koretsune, Y., Sasano, T., et al. (2022) · Circulation Journal · doi:10.1253/circj.cj-20-1212 · Cited by 132
A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension
Bunclark, K., Newnham, M., Chiu, Y., Ruggiero, A., Villar, S. S., Cannon, J. E., Coghlan, G., Corris, P. A., Howard, L., Jenkins, D. P., et al. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14649 · Cited by 130
Oral Anticoagulant Type and Outcomes After Transcatheter Aortic Valve Replacement
Jochheim, D., Barbanti, M., Capretti, G., Stefanini, G. G., Hapfelmeier, A., Zadrozny, M., Baquet, M., Fischer, J., Theiss, H. D., Todaro, D., et al. (2019) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2019.03.003 · Cited by 128
Apixaban or Warfarin in Patients with an On-X Mechanical Aortic Valve
Wang, T. Y., Svensson, L. G., Wen, J., Vekstein, A. M., Gerdisch, M., Rao, V. U., Moront, M. G., Johnston, D., Lópes, R. D., Chavez, A., et al. (2023) · NEJM Evidence · doi:10.1056/evidoa2300067 · Cited by 134
The use of novel oral anticoagulants compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarction
Jones, D. A., Wright, P., Alizadeh, M. A., Fhadil, S., Rathod, K. S., Guttmann, O. P., Knight, C. J., Timmis, A., Baumbach, A., Wragg, A., et al. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa096 · Cited by 124
Non–Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease
Renda, G., Ricci, F., Giugliano, R. P., & Caterina, R. D. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.12.038 · Cited by 131
Bleeding and thrombosis associated with ventricular assist device therapy
Shah, P. M., Tantry, U. S., Bliden, K. P., & Gurbel, P. A. (2017) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2017.05.008 · Cited by 124
Drug–Drug Interactions with Direct Oral Anticoagulants
Foerster, K. I., Hermann, S. A., Mikus, G., & Haefeli, W. E. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00879-x · Cited by 127
Antithrombotic Agents
Chan, N., & Weitz, J. I. (2019) · Circulation Research · doi:10.1161/circresaha.118.313155 · Cited by 120
Atrial Fibrillation and Ischemic Stroke: A Clinical Review
Migdady, I., Russman, A., & Buletko, A. B. (2021) · Seminars in Neurology · doi:10.1055/s-0041-1726332 · Cited by 130
Dabigatran Versus Warfarin After Bioprosthesis Valve Replacement for the Management of Atrial Fibrillation Postoperatively: DAWA Pilot Study
Durães, A. R., Roriz, P. D. S., Nunes, B. D. A., Albuquerque, F. P. E., de Bulhões, F. V., Fernandes, A. M. S., & Aras, R. (2016) · Drugs in R&D · doi:10.1007/s40268-016-0124-1 · Cited by 114
Dabigatran is Less Effective Than Warfarin at Attenuating Mechanical Heart Valve‐Induced Thrombin Generation
Jaffer, I., Stafford, A. R., Fredenburgh, J. C., Whitlock, R. P., Chan, N., & Weitz, J. I. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002322 · Cited by 112
Practical Management of Anticoagulation in Patients With Atrial Fibrillation
Kovacs, R. J., Flaker, G. C., Saxonhouse, S. J., Doherty, J. U., Birtcher, K. K., Cuker, A. C., Davidson, B. L., Giugliano, R. P., Granger, C. B., Jaffer, A. K., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.01.049 · Cited by 114
Evolving Treatments for Arterial and Venous Thrombosis
Chan, N., Eikelboom, J. W., & Weitz, J. I. (2016) · Circulation Research · doi:10.1161/circresaha.116.306925 · Cited by 113
Anticoagulation in atrial fibrillation
Steinberg, B. A., & Piccini, J. P. (2014) · BMJ · doi:10.1136/bmj.g2116 · Cited by 104
Anticoagulation During Pregnancy
Alshawabkeh, L. I., Economy, K. E., & Valente, A. M. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.06.076 · Cited by 106
Antithrombotic Therapy for Primary and Secondary Prevention of Ischemic Stroke
Greco, A., Occhipinti, G., Giacoppo, D., Agnello, F. G., Laudani, C., Spagnolo, M., Mauro, M. S., Rochira, C., Finocchiaro, S., Mazzone, P. M., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.07.025 · Cited by 115
How to define valvular atrial fibrillation?
Fauchier, L., Philippart, R., Clémenty, N., Bourguignon, T., Angoulvant, D., Ivanés, F., Babuty, D., & Bernard, A. (2015) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2015.06.002 · Cited by 108
Calcific Aortic Stenosis: A Review
Otto, C. M., Newby, D. E., & Hillis, G. S. (2024) · JAMA · doi:10.1001/jama.2024.16477 · Cited by 97
Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial
Lorentz, C. U., Verbout, N. G., Wallisch, M., Hagen, M. W., Shatzel, J. J., Olson, S. R., Puy, C., Hinds, M. T., McCarty, O. J. T., Gailani, D., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.312328 · Cited by 104
Increased Thromboembolic Events With Dabigatran Compared With Vitamin K Antagonism in Left Ventricular Assist Device Patients
Andreas, M., MOAYEDIFAR, R., Wieselthaler, G. M., Wolzt, M., Riebandt, J., Haberl, T., Angleitner, P., Schlöglhofer, T., Wiedemann, D., Schima, H., et al. (2017) · Circulation Heart Failure · doi:10.1161/circheartfailure.116.003709 · Cited by 103
Dabigatran Etexilate and Risk of Myocardial Infarction, Other Cardiovascular Events, Major Bleeding, and All‐Cause Mortality: A Systematic Review and Meta‐analysis of Randomized Controlled Trials
Douxfils, J., Buckinx, F., Mullier, F., Minet, V., Rabenda, V., Reginster, J., Hainaut, P., Bruyère, O., & Dogné, J. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000515 · Cited by 103
2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation
Chao, T., Joung, B., Takahashi, Y., Lim, T. W., Choi, E., Chan, Y., Guo, Y., Sriratanasathavorn, C., Oh, S., Okumura, K., et al. (2021) · Journal of Arrhythmia · doi:10.1002/joa3.12652 · Cited by 105
Mechanical Versus Bioprosthetic Aortic Valve Replacement in Middle-Aged Adults: A Systematic Review and Meta-Analysis
Zhao, D. F., Seco, M., Wu, J. J., Edelman, J. B., Wilson, M. K., Vallely, M. P., Byrom, M. J., & Bannon, P. G. (2016) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2015.10.092 · Cited by 99
“The effect of novel oral anticoagulant use in MV patients is still largely unstudied as well, though the Dabigatran Etexilate in Patients With Mechanical Heart Valves (RE-ALIGN) study found that Dabigatran in MV patients was associated with increased rates of thromboembolic and bleeding complications, as compared with…”
Background
Factors XI and XII as Targets for New Anticoagulants
Weitz, J. I., & Fredenburgh, J. C. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00019 · Cited by 98
2024 EACTS Guidelines on perioperative medication in adult cardiac surgery
Jeppsson, A., (Sweden), (.-C., Rocca, B., (Italy), (.-C., Hansson, E. C., (Sweden), Guðbjartsson, T., (Iceland), James, S. K., (Sweden), et al. (2024) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezae355 · Cited by 114
Risk of Major Gastrointestinal Bleeding With New vs Conventional Oral Anticoagulants: A Systematic Review and Meta-analysis
Gu, Z., Wei, A., Zhang, C., Wang, X., Zhang, L., Shen, L., Li, Z., Pan, M.-M., Liu, X.-Y., Pu, J., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.05.056 · Cited by 102
Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?
Alamneh, E. A., Chalmers, L., & Bereznicki, L. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0161-8 · Cited by 98
Secondary stroke prevention in people with atrial fibrillation: treatments and trials
Seiffge, D. J., Cancelloni, V., Räber, L., Paciaroni, M., Metzner, A., Kirchhof, P. F., Fischer, U., Werring, D. J., Shoamanesh, A., & Caso, V. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00037-1 · Cited by 101
Atualização das Diretrizes Brasileiras de Valvopatias – 2020
Tarasoutchi, F., Montera, M. W., Ramos, A. I. D. O., Sampaio, R. O., Rosa, V. E. E., Accorsi, T. A. D., de Santis, A., Fernandes, J. R. C., Pires, L. J. T., Spina, G. S., et al. (2020) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20201047 · Cited by 98
Atrial fibrillation: stroke prevention
Chao, T., Potpara, T., & Lip, G. Y. H. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100797 · Cited by 103
“67 For AF patients with MS, there were no randomized trials to compare DOACs and warfarin until the INVICTUS trial was published.”
Direct‐acting oral anticoagulants: pharmacology, indications, management, and future perspectives
Gómez‐Outes, A., Suárez‐Gea, M. L., Lecumberri, R., Terleira‐Fernández, A. I., & Vargas, E. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12610 · Cited by 96
Outcomes of Direct Oral Anticoagulants in Patients With Mitral Stenosis
Kim, J. Y., Kim, S., Myong, J., Kim, Y. R., Kim, T., Kim, J., Jang, S.-W., Oh, Y., Lee, M. Y., & Rho, T. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.12.047 · Cited by 93
“Furthermore, the RE-ALIGN (Randomized, Phase II Study to Evaluate the Safety and Pharmacokinetics of Oral Dabigatran Etexilate in Patients after Heart Valve Replacement) trial using dabigatran in patients with prosthetic heart valves demonstrated that dabigatran increased both embolic and bleeding events (24).”
Background
The optimal management of anti-thrombotic therapy after valve replacement: certainties and uncertainties
Iung, B., & Rodés‐Cabau, J. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu365 · Cited by 88
Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients
Testa, S., Paoletti, O., Giorgi‐Pierfranceschi, M., & Pan, A. (2020) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02331-1 · Cited by 89
“DOAC represent the treatment of choice for many clinical indications, such as the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and the prevention and treatment of venous thromboembolism (VTE), and VKA antagonists remain the only available drugs to prevent valve th…”
Background
2020 Clinical practice guidelines for Chronic heart failure
Russian Society of Cardiology (2020) · Russian Journal of Cardiology · doi:10.15829/29/1560-4071-2020-4083 · Cited by 88
Joint EAPCI/ACVC expert consensus document on percutaneous ventricular assist devices
Chieffo, A., Dudek, D., Hassager, C., Combes, A., Gramegna, M., Halvorsen, S., Huber, K., Kunadian, V., Malý, J., Møller, J. E., et al. (2021) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuab015 · Cited by 87
Perioperative Guidelines on Antiplatelet and Anticoagulant Agents: 2022 Update
Moster, M., & Bolliger, D. (2022) · Current anesthesiology reports · doi:10.1007/s40140-021-00511-z · Cited by 87
Factor XI Inhibitors for Prevention and Treatment of Venous Thromboembolism: A Review on the Rationale and Update on Current Evidence
Nopp, S., Kraemmer, D., & Ay, C. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.903029 · Cited by 89
“In dialysis patients, where the risk of bleeding is exceptionally high (32), the benefit-to-risk ratio of oral anticoagulants, in general, is still debated as observational studies report excess bleeding rates with VKA and DOAC (33, 34).”
BackgroundInfluential
Antithrombotic Therapy After Transcatheter Aortic Valve Replacement
Guedeney, P., Mehran, R., Collet, J., Claessen, B. E. P. M., ten Berg, J. M., & Dangas, G. (2019) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.118.007411 · Cited by 87
Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: A randomized clinical trial
Shim, C. Y., Seo, J., Kim, Y. J., Lee, S. H., Caterina, R. D., Lee, S. H., Hong, G.-R., Shin, D., Seo, J., Lee, C. J., et al. (2021) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2021.01.127 · Cited by 87
Novel antithrombotic strategies for treatment of venous thromboembolism
Weitz, J. I., & Chan, N. (2020) · Blood · doi:10.1182/blood.2019000919 · Cited by 84
When Direct Oral Anticoagulants Should Not Be Standard Treatment
Bejjani, A., Khairani, C. D., Assi, A. A., Piazza, G., Sadeghipour, P., Talasaz, A. H., Fanikos, J. R., Connors, J. M., Siegal, D. M., Barnes, G. D., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.10.038 · Cited by 89
Dabigatran, bleeding, and the regulators
Moore, T. J., Cohen, M. R., & Mattison, D. R. (2014) · BMJ · doi:10.1136/bmj.g4517 · Cited by 83
2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. Executive summary
Frendl, G., Sodickson, A., Chung, M. K., Waldo, A. L., Gersh, B. J., Tisdale, J. E., Calkins, H. G., Aranki, S. F., Kaneko, T., Cassivi, S. D., et al. (2014) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2014.06.037 · Cited by 83
Emerging anticoagulant strategies
Fredenburgh, J. C., Gross, P. L., & Weitz, J. I. (2016) · Blood · doi:10.1182/blood-2016-09-692996 · Cited by 82
Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients With Atrial Fibrillation After TAVR
Kawashima, H., Watanabe, Y., Hioki, H., Kozuma, K., Kataoka, A., Nakashima, M., Nagura, F., Nara, Y., Yashima, F., Tada, N., et al. (2020) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2020.09.013 · Cited by 82
2025 ESC/EACTS Guidelines for the management of valvular heart disease
Praz, F., Borger, M. A., Lanz, J., Cuartas, M. M., Abreu, A., Adamo, M., Marsan, N. A., Barili, F., Bonaros, N. E., Cosyns, B., et al. (2025) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezaf276 · Cited by 97
Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve
Jawitz, O. K., Wang, T. Y., Lópes, R. D., Chavez, A., Boyer, B., Kim, H., Anstrom, K. J., Becker, R. C., Blackstone, E. H., Ruel, M., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.06.014 · Cited by 81
Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two‐year outcomes after the study closure
Pengo, V., Hoxha, A., Andréoli, L., Tincani, A., Silvestri, E., Prisco, D., Fierro, T., Gresele, P., Cafolla, A., Micheli, V. D., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15158 · Cited by 79
Factor XI and factor XII as targets for new anticoagulants
Weitz, J. I. (2016) · Thrombosis Research · doi:10.1016/s0049-3848(16)30363-2 · Cited by 78
New anticoagulants: Moving beyond the direct oral anticoagulants
Fredenburgh, J. C., & Weitz, J. I. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15126 · Cited by 81
Updates in Anticoagulation Therapy Monitoring
McRae, H. L., Militello, L., & Refaai, M. A. (2021) · Biomedicines · doi:10.3390/biomedicines9030262 · Cited by 77
Management of Mechanical Prosthetic Heart Valve Thrombosis
Jiménez, C. E. S., Papolos, A., Kenigsberg, B. B., Ben‐Dor, I., Satler, L. F., Waksman, R., Cohen, J. E., & Rogers, T. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.03.412 · Cited by 77
Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants
Enriquez, A. A., Lip, G. Y. H., & Baranchuk, A. M. (2015) · EP Europace · doi:10.1093/europace/euv030 · Cited by 75
Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation
Salazar, C. A., del Aguila, D., & Cordova-Ramos, E. G. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009893.pub2 · Cited by 76
Usefulness of Direct Oral Anticoagulants in Adult Congenital Heart Disease.
Pujol, C., Niesert, A.-C., Engelhardt, A., Schoen, P., Kusmenkov, E., Pittrow, D., Ewert, P., & Kaemmerer, H. (2016) · American Journal of Cardiology · doi:10.1016/j.amjcard.2015.10.062 · Cited by 71
Neutrophil α-defensins promote thrombosis in vivo by altering fibrin formation, structure, and stability
Abu‐Fanne, R., Stepanova, V. V., Игоревич, Л. Р., Abdeen, S., Bdeir, K. H., Higazi, M., Maraga, E., Nagaswami, C., Mukhitov, A. R., Weisel, J. W., et al. (2018) · Blood · doi:10.1182/blood-2018-07-861237 · Cited by 74
Mechanical circulatory support: balancing bleeding and clotting in high-risk patients
Kreuziger, L. B., & Massicotte, M. P. (2015) · Hematology · doi:10.1182/asheducation-2015.1.61 · Cited by 73
Factor XI inhibitors: cardiovascular perspectives
Caterina, R. D., Prisco, D., & Eikelboom, J. W. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac464 · Cited by 79
Oral anticoagulation: a critique of recent advances and controversies
Pirmohamed, M., Kamali, F., Daly, A. K., & Wadelius, M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.01.003 · Cited by 72
Current use and safety of novel oral anticoagulants in adults with congenital heart disease: results of a nationwide analysis including more than 44 000 patients
Freisinger, E., Gerß, J., Makowski, L., Marschall, U., Reinecke, H., Baumgartner, H., Koeppe, J., & Diller, G. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa844 · Cited by 71
Antithrombotic Therapy After Transcatheter Aortic Valve Replacement
Capodanno, D., Collet, J., Dangas, G., Montalescot, G., ten Berg, J. M., Windecker, S., & Angiolillo, D. J. (2021) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2021.06.020 · Cited by 71
New-Onset Atrial Fibrillation After Cardiac Surgery: Pathophysiology, Prophylaxis, and Treatment
Ломиворотов, В. В., Efremov, S. M., Pokushalov, E. A., & Karaskov, A. M. (2015) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2015.08.003 · Cited by 73
Management of People With a Fontan Circulation: a Cardiac Society of Australia and New Zealand Position statement
Zentner, D., Celermajer, D. S., Gentles, T. L., d’Udekem, Y., Ayer, J. G., Blue, G. M., Bridgman, C., Burchill, L. J., Cheung, M. M. H., Cordina, R., et al. (2019) · Heart Lung and Circulation · doi:10.1016/j.hlc.2019.09.010 · Cited by 71
“Of note, DOACs have failed in trials of artificial valves [256] and circuits [257], so their effectiveness in the setting of graft material”
Background
Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation
Butt, J. H., Backer, O. D., Olesen, J. B., Gerds, T. A., Havers‐Borgersen, E., Gislason, G., Torp-Pedersen, C. T., Søndergaard, L., Køber, L., & Fosbøl, E. L. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz064 · Cited by 70
The definition of valvular and non-valvular atrial fibrillation: results of a physicians' survey
Molteni, M., Friz, H. P., Primitz, L., Marano, G., Boracchi, P., & Cimminiello, C. (2014) · EP Europace · doi:10.1093/europace/euu178 · Cited by 71
“The RE-ALIGN study results advise against the use of the NOAC dabigatran in patients with mechanical heart valve prostheses.(11) Definitions of valvular/non-valvular AF adopted by authoritative guidelines have changed in their different editions and sometimes they are in contradiction with each other.”
Result
A Review on the Green Synthesis of Benzimidazole Derivatives and Their Pharmacological Activities
Nardi, M., Cano, N. C. H., Simeonov, S. P., Bence, R., Kurutos, A., Scarpelli, R., Wunderlin, D. A., & Procopio, A. (2023) · Catalysts · doi:10.3390/catal13020392 · Cited by 73
Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT‐AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation)
Thomas, K. L., Jackson, L. R., Shrader, P., Ansell, J., Fonarow, G. C., Gersh, B. J., Kowey, P. R., Mahaffey, K. W., Singer, D. E., Thomas, L. E., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006475 · Cited by 68
NOAC monotherapy in patients with concomitant indications for oral anticoagulation undergoing transcatheter aortic valve implantation
Geis, N., Kiriakou, C., Chorianopoulos, E., Uhlmann, L., Katus, H., & Bekeredjian, R. (2018) · Clinical Research in Cardiology · doi:10.1007/s00392-018-1247-x · Cited by 62
Diagnostic and Therapeutic Management of Upper Extremity Deep Vein Thrombosis
Bosch, F. T. M., Nisio, M. D., Buller, H. R., & van Es, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072069 · Cited by 67
“For example, there was an increased risk of thromboembolic and bleeding complications in patients with a mechanical heart valve treated with dabigatran in the RE-ALIGN study [45].”
Background
Antithrombotic Therapy to Prevent Recurrent Strokes in Ischemic Cerebrovascular Disease
Brutto, V. J. D., Chaturvedi, S., Diener, H., Romano, J. G., & Sacco, R. L. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.06.039 · Cited by 71
“Warfarin was superior to dabigatran in patients with mechanical heart valves, both in terms of efficacy and safety (72).”
Background
New oral anticoagulant agents – general features and outcomes in subsets of patients
Schulman, S. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-09-0803 · Cited by 66
“Dabigatran for prevention of stroke or systemic embolism in mechanical heart valves was first evaluated in animal models and subsequently in the phase II study (27).”
Background
European Primary Care Cardiovascular Society (EPCCS) consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care
Hobbs, R. F., Taylor, C. J., Geersing, G. J., Rutten, F. H., Brouwer, J. R., & on behalf of the European Primary Care Cardiovascular Society (EPCCS) SPAF working group (2015) · European Journal of Preventive Cardiology · doi:10.1177/2047487315571890 · Cited by 67
“The only trial to date evaluating a NOAC in patients with mechanical heart valves was halted after 250 enrolled patients, since the NOAC, used in higher dosage than for NVAF, was associated with more strokes and more bleeds than the vitamin K antagonist [21].”
Background
Prediction of Optimal Warfarin Maintenance Dose Using Advanced Artificial Neural Networks
Grossi, E., Podda, G. M., Pugliano, M., Gabba, S., Verri, A., Carpani, G., Buscema, M., Casazza, G., & Cattaneo, M. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.212 · Cited by 63
Stroke risk stratification in atrial fibrillation: a review of common risk factors
Oladiran, O. D., & Nwosu, I. F. (2019) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.1080/20009666.2019.1593781 · Cited by 69
“which compared Dabigatran an oral direct thrombin inhibitor against Warfarin in AF patients with mechanical valve [33].”
Background
2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter
Heidenreich, P. A., Solis, P., Estes, N. A. M., Fonarow, G. C., Jurgens, C. Y., Marine, J. E., McManus, D. D., & McNamara, R. L. (2016) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/hcq.0000000000000018 · Cited by 62
Efficacy and safety of novel oral anticoagulants in patients with bioprosthetic valves
Yadlapati, A., Groh, C. A., Malaisrie, S. C., Gajjar, M. M., Kruse, J. T., Meyers, S. N., & PASSMAN, R. S. (2015) · Clinical Research in Cardiology · doi:10.1007/s00392-015-0919-z · Cited by 61
Continued Versus Interrupted Oral Anticoagulation During Transfemoral Transcatheter Aortic Valve Implantation and Impact of Postoperative Anticoagulant Management on Outcome in Patients With Atrial Fibrillation
Mangner, N., Crusius, L., Haußig, S., Woitek, F. J., Kiefer, P., Stachel, G., Leontyev, S., Schlotter, F., Spindler, A., Höllriegel, R., et al. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.12.042 · Cited by 61
Potential of Superhydrophobic Surface for Blood-Contacting Medical Devices
Wu, X. H., Liew, Y. K., Mai, C., & Then, Y. Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073341 · Cited by 59
DOAC–associated bleeding, hemostatic strategies, and thrombin generation assays - a review of the literature
Shaw, J. R., Castellucci, L. A., Siegal, D. M., & Carrier, M. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2022.11.029 · Cited by 58
Quality of oral anticoagulation with phenprocoumon in regular medical care and its potential for improvement in a telemedicine-based coagulation service – results from the prospective, multi-center, observational cohort study thrombEVAL
Prochaska, J. H., Göbel, S., Keller, K., Coldewey, M., Ullmann, A., Lamparter, H., Jünger, C., Al‐Bayati, Z., Baer, C., Walter, U., et al. (2015) · BMC Medicine · doi:10.1186/s12916-015-0268-9 · Cited by 58
2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter
Heidenreich, P. A., Solis, P., Estes, N. A. M., Fonarow, G. C., Jurgens, C. Y., Marine, J. E., McManus, D. D., & McNamara, R. L. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.521 · Cited by 58

Authors: Eikelboom, J. W., Connolly, S. J., Brueckmann, M., Granger, C. B., Kappetein, A. P., Mack, M. J., Blatchford, J., Devenny, K., Friedman, J., Guiver, K., Harper, R., Khder, Y., Lobmeyer, M. T., Maas, H., Voigt, J.-U., Simoons, M. L., & Van de Werf, F.
Affiliations: Hamilton Health Sciences (CA)
Boehringer Ingelheim (Germany) (DE)
Duke University (US)
Erasmus MC (NL)
Heart Hospital Baylor Plano (US)
Boehringer Ingelheim (United Kingdom) (GB)
Boehringer Ingelheim (United States) (US)
Boehringer Ingelheim (France) (FR)
KU Leuven (BE)
ORCID: Eikelboom, John W.
Connolly, Stuart J.
Brueckmann, Martina
Granger, Christopher B.
Kappetein, Arie P.
Mack, Michael J.
Blatchford, Jon
Guiver, Kelly
Khder, Yasser
Lobmeyer, Maximilian T.
Voigt, Jens-Uwe
Simoons, Maarten L.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2013-09-26
Volume: 369
Issue: 13
Pages: 1206-1214
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1300615
OpenAlex: W2016875529
Cited by: 1,506
References: 27
Citations by year: 2026: 52 · 2025: 84 · 2024: 111 · 2023: 95 · 2022: 102 · 2021: 140 · 2020: 130 · 2019: 113 · 2018: 119 · 2017: 128 · 2016: 116 · 2015: 131 · 2014: 147 · 2013: 36
FWCI: 97.35
Type: journal article
Language: en
Open access: closed
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Pure Amsterdam UMC (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Keywords: dabigatran, warfarin, mechanical heart valves, direct thrombin inhibitors, anticoagulation, thromboembolism, bleeding complications, pericardial bleeding, stroke, aortic valve replacement, mitral valve replacement, dose adjustment
MeSH terms: Dabigatran, Aged, Anticoagulants, Atrial Fibrillation, Benzimidazoles, Female, Heart Valve Prosthesis, Hemorrhage, Humans, Male, Middle Aged, Thromboembolism, Warfarin, beta-Alanine, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Dabigatran versus Warfarin in Patients with Mechanical Heart Valves

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks